Regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in real-world practice in the United States (US): Final analysis of the prospective, observational REFINE study

被引：0
|
作者：
Kaseb, Ahmed Omar
Cabrera, Roniel
Iyer, Renuka
Parikh, Neehar
Kalman, Richard
Ozgurdal, Kirhan
Khan, Javeed
Babajanyan, Svetlana
Finn, Richard S.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[2] Univ Florida, Gainesville, FL USA
[3] Roswell Pk Canc Inst, Buffalo, NY USA
[4] Univ Michigan Med, Ann Arbor, MI USA
[5] Einstein Healthcare Network, Philadelphia, PA USA
[6] Bayer, Basel, Switzerland
[7] Bayer PLC, Reading, Berks, England
[8] Bayer Healthcare, Whippany, NJ USA
[9] UCLA Med Ctr, Santa Monica, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16114
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Real-world clinical effectiveness of sorafenib among patients with unresectable hepatocellular carcinoma at two centers in the United States
    Li, Daneng
    Gruber, Stephen B.
    Iyer, Shrividya
    Gupta, Sanjay
    Tejani, Mohamedtaki
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2023, 15 (10) : 1796 - 1806
  • [32] Safety and Effectiveness of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice: An Observational Post-Marketing Study in Japan
    Junji Furuse
    Namiki Izumi
    Kenta Motomura
    Yoshitaka Inaba
    Yoshio Katamura
    Yasuteru Kondo
    Kazuhisa Yabushita
    Katsuaki Motoyoshi
    Masatoshi Kudo
    Drugs - Real World Outcomes, 2023, 10 : 195 - 205
  • [33] Safety and Effectiveness of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice: An Observational Post-Marketing Study in Japan
    Furuse, Junji
    Izumi, Namiki
    Motomura, Kenta
    Inaba, Yoshitaka
    Katamura, Yoshio
    Kondo, Yasuteru
    Yabushita, Kazuhisa
    Motoyoshi, Katsuaki
    Kudo, Masatoshi
    DRUGS-REAL WORLD OUTCOMES, 2023, 10 (02) : 195 - 205
  • [34] LENVATINIB FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA IN REAL-WORLD PRACTICE - MULTICENTER ANALYSIS OF PROGNOSTIC FACTORS
    Hiraoka, Atsushi
    Kumada, Takashi
    Atsukawa, Masanori
    Hirooka, Masashi
    Ishikawa, Toru
    Kunihiko, Tsuji
    Takaguchi, Koichi
    Kariyama, Kazuya
    Itobayashi, Ei
    Tajiri, Kazuto
    Shimada, Noritomo
    Shibata, Hiroshi
    Ochi, Hironori
    Tada, Toshifumi
    Toyoda, Hidenori
    Nouso, Kazuhiro
    Tsutsui, Akemi, Sr.
    Nagano, Takuya
    Itokawa, Norio
    Hayama, Korenobu
    Imai, Michitaka
    Joko, Kouji
    Koizumi, Yohei
    Hiasa, Yoichi
    Michitaka, Kojiro
    Kudo, Masatoshi
    HEPATOLOGY, 2019, 70 : 217A - 218A
  • [35] Real-world registry of patients with unresectable hepatocellular carcinoma: The OREIOS study.
    Chan, Stephen Lam
    Ryu, Min-Hee
    Waked, Imam
    Shao, Yu Yun
    Tai, Wai Meng David
    Breder, Valeriy
    Alolayan, Ashwaq
    Ganguly, Sandip
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS618 - TPS618
  • [36] Real-world effectiveness of lenvatinib monotherapy in previously treated unresectable hepatocellular carcinoma in US clinical practice
    Singal, Amit G.
    Nagar, Saurabh P.
    Hitchens, Abby
    Davis, Keith L.
    Iyer, Shrividya
    CANCER REPORTS, 2023, 6 (01)
  • [37] Regorafenib combined with a PD-1 inhibitor in the second-line setting for unresectable hepatocellular carcinoma in real-world practice
    Bi, Huaqiang
    Pei, Jun
    Ma, Kuansheng
    Zhang, Yanling
    Aprile, Giuseppe
    Moris, Dimitrios
    Mendez-Sanchez, Nahum
    Samant, Hrishikesh
    Sun, Ximin
    Xia, Feng
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (01) : 368 - 376
  • [38] Final analysis of serum biomarkers in patients (pts) from the phase III study of lenvatinib (LEN) vs sorafenib (SOR) in unresectable hepatocellular carcinoma (uHCC) [REFLECT]
    Finn, R. S.
    Kudo, M.
    Cheng, A-L.
    Wyrwicz, L.
    Ngan, R.
    Blanc, J. F.
    Baron, A. D.
    Vogel, A.
    Ikeda, M.
    Piscaglia, F.
    Han, K-H.
    Qin, S.
    Minoshima, Y.
    Kanekiyo, M.
    Ren, M.
    Dairiki, R.
    Tamai, T.
    Dutcus, C. E.
    Funahashi, Y.
    Evans, T. R. J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [39] Real-world effectiveness of lenvatinib monotherapy among unresectable hepatocellular carcinoma patients treated in United States clinical practices.
    Singal, Amit G.
    Nagar, Saurabh P.
    Hitchens, Abigail
    Iyer, Shrividya
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [40] What can real-world data teach us about treating patients with unresectable hepatocellular carcinoma?
    Dalbeni, A.
    Cattazzo, F.
    Natola, L. A.
    Zoncape, M.
    Faccincani, D.
    Stefanini, B.
    Ravaioli, F.
    Villani, R.
    Auriemma, A.
    Sacerdoti, D.
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2025,
12345